18F-FDG PET/CT for the Assessment of Myocardial Sarcoidosis

  • Hicham Skali
  • Allison R. Schulman
  • Sharmila DorbalaEmail author
Nuclear Cardiology (V Dilsizian, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Nuclear Cardiology


Cardiac involvement portends a poor prognosis in patients with sarcoidosis. However, due to the nonspecific clinical manifestations of the disease, patchy myocardial involvement, and the limited diagnostic yield of diagnostic tests, early diagnosis of cardiac sarcoidosis has been exceedingly difficult. As a result, there is no standardized approach for the early diagnosis of cardiac sarcoidosis. Imaging modalities that can both identify disease and predict response to therapy are paramount to improve management of cardiac sarcoidosis. 18F-FDG PET has many practical advantages in assessing disease activity and monitoring treatment response in patients with cardiac sarcoidosis. Accumulating data support the growing role of 18F-fluorodeoxyglucose (18F-FDG) PET in the diagnosis and risk stratification of patients with cardiac sarcoidosis.


Cardiac sarcoidosis 18F-FDG PET Myocardial sarcoidosis 


Conflicts of Interest

Hicham Skali declares that he has no conflict of interest.

Allison R. Schulman declares that she has no conflict of interest.

Sharmila Dorbala has received salary support from a research grant from the National Institutes of Health (5K23HL092299-03); has received grant support from Astellas Global Pharma Development, Bracco Diagnostics; has received travel/accommodations expenses covered or reimbursed from RSNA, ASNC.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation. 1978;58:1204–11.PubMedCrossRefGoogle Scholar
  2. 2.
    Nomura S, Funabashi N, Tsubura M, Uehara M, Shiina Y, Daimon M, et al. Cardiac sarcoidosis evaluated by multimodality imaging. Int J Cardiol. 2011;150:e81–4.PubMedCrossRefGoogle Scholar
  3. 3.
    Kim JS, Judson MA, Donnino R, Gold M, Cooper Jr LT, Prystowsky EN, et al. Cardiac sarcoidosis. Am Heart J. 2009;157:9–21.PubMedCrossRefGoogle Scholar
  4. 4.
    Sharma OP, Maheshwari A, Thaker K. Myocardial sarcoidosis. Chest. 1993;103:253–8.PubMedCrossRefGoogle Scholar
  5. 5.
    • Youssef G, Beanlands RS, Birnie DH, Nery PB. Cardiac sarcoidosis: applications of imaging in diagnosis and directing treatment. Heart. 2011;97:2078–87. Excellent review describing multimodality imaging of cardiac sarcoidosis and its value in diagnosis and management.PubMedCrossRefGoogle Scholar
  6. 6.
    •• Youssef G, Leung E, Mylonas I, Nery P, Williams K, Wisenberg G, et al. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. J Nucl Med. 2012;53:241–8. Meta-analysis of 7 studies comparing the accuracy of 18F-FDG PET for the diagnosis of cardiac sarcoidosis.PubMedCrossRefGoogle Scholar
  7. 7.
    Matsui Y, Iwai K, Tachibana T, Fruie T, Shigematsu N, Izumi T, et al. Clinicopathological study of fatal myocardial sarcoidosis. Ann N Y Acad Sci. 1976;278:455–69.PubMedCrossRefGoogle Scholar
  8. 8.
    Hiraga H, Hiroe M, Iwai K, et al. Guideline for the diagnosis of cardiac sarcoidosis: study report on Diffuse Pulmonary Diseases (in Japanese). 1993:23–4.Google Scholar
  9. 9.
    •• Tahara N, Tahara A, Nitta Y, Kodama N, Mizoguchi M, Kaida H, et al. Heterogeneous myocardial FDG uptake and the disease activity in cardiac sarcoidosis. JACC Cardiovasc Imaging. 2010;3:1219–28. First study to use quantitative assessment of FDG uptake in patients with cardiac sarcoidosis compared with normal and dilated cardiomyopathy patients.PubMedCrossRefGoogle Scholar
  10. 10.
    Diagnostic standard and guidelines for sarcoidosis. Jpn J Sarcoidosis and Granulomatous Disorders (in Japanese). 2007;27:89–102.Google Scholar
  11. 11.
    Roberts WC, McAllister Jr HA, Ferrans VJ. Sarcoidosis of the heart. A clinicopathologic study of 35 necropsy patients (group 1) and review of 78 previously described necropsy patients (group 11). Am J Med. 1977;63:86–108.PubMedCrossRefGoogle Scholar
  12. 12.
    Uemura A, Morimoto S, Hiramitsu S, Kato Y, Ito T, Hishida H. Histologic diagnostic rate of cardiac sarcoidosis: evaluation of endomyocardial biopsies. Am Heart J. 1999;138(2 Pt 1):299–302.PubMedCrossRefGoogle Scholar
  13. 13.
    Ratner SJ, Fenoglio Jr JJ, Ursell PC. Utility of endomyocardial biopsy in the diagnosis of cardiac sarcoidosis. Chest. 1986;90:528–33.PubMedCrossRefGoogle Scholar
  14. 14.
    Yamagishi H, Shirai N, Takagi M, Yoshiyama M, Akioka K, Takeuchi K, et al. Identification of cardiac sarcoidosis with (13)N-NH(3)/(18)F-FDG PET. J Nucl Med. 2003;44:1030–6.PubMedGoogle Scholar
  15. 15.
    Takeda N, Yokoyama I, Hiroi Y, Sakata M, Harada T, Nakamura F, et al. Positron emission tomography predicted recovery of complete A-V nodal dysfunction in a patient with cardiac sarcoidosis. Circulation. 2002;105:1144–5.PubMedCrossRefGoogle Scholar
  16. 16.
    •• Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med. 2007;357:2153–65. This is an excellent and comprehensive review covering discussions on etiology, genetics, immunopathogenesis, diagnosis, clinical manifestations, and treatment of sarcoidosis.PubMedCrossRefGoogle Scholar
  17. 17.
    Doughan AR, Williams BR. Cardiac sarcoidosis. Heart. 2006;92:282–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Gotthardt M, Bleeker-Rovers CP, Boerman OC, Oyen WJ. Imaging of inflammation by PET, conventional scintigraphy, and other imaging techniques. J Nucl Med. 2010;51:1937–49.PubMedCrossRefGoogle Scholar
  19. 19.
    Nishiyama Y, Yamamoto Y, Fukunaga K, Takinami H, Iwado Y, Satoh K, et al. Comparative evaluation of 18F-FDG PET and 67 Ga scintigraphy in patients with sarcoidosis. J Nucl Med. 2006;47:1571–6.PubMedGoogle Scholar
  20. 20.
    Ishimaru S, Tsujino I, Takei T, Tsukamoto E, Sakaue S, Kamigaki M, et al. Focal uptake on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. Eur Heart J. 2005;26:1538–43.PubMedCrossRefGoogle Scholar
  21. 21.
    Okumura W, Iwasaki T, Toyama T, Iso T, Arai M, Oriuchi N, et al. Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med. 2004;45:1989–98.PubMedGoogle Scholar
  22. 22.
    Pandya C, Brunken RC, Tchou P, Schoenhagen P, Culver DA. Detecting cardiac involvement in sarcoidosis: a call for prospective studies of newer imaging techniques. Eur Respir J. 2007;29:418–22.PubMedCrossRefGoogle Scholar
  23. 23.
    Mehta D, Lubitz SA, Frankel Z, Wisnivesky JP, Einstein AJ, Goldman M, et al. Cardiac involvement in patients with sarcoidosis: diagnostic and prognostic value of outpatient testing. Chest. 2008;133:1426–35.PubMedCrossRefGoogle Scholar
  24. 24.
    Newsholme P, Newsholme EA. Rates of utilization of glucose, glutamine and oleate and formation of end-products by mouse peritoneal macrophages in culture. Biochem J. 1989;261:211–8.PubMedGoogle Scholar
  25. 25.
    Isiguzo M, Brunken R, Tchou P, Xu M, Culver DA. Metabolism-perfusion imaging to predict disease activity in cardiac sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2011;28:50–5.PubMedGoogle Scholar
  26. 26.
    Treglia G, Taralli S, Giordano A. Emerging role of whole-body 18F-fluorodeoxyglucose positron emission tomography as a marker of disease activity in patients with sarcoidosis: a systematic review. Sarcoidosis Vasc Diffuse Lung Dis. 2011;28:87–94.PubMedGoogle Scholar
  27. 27.
    Langah R, Spicer K, Gebregziabher M, Gordon L. Effectiveness of prolonged fasting 18f-FDG PET-CT in the detection of cardiac sarcoidosis. J Nucl Cardiol. 2009;16:801–10.PubMedCrossRefGoogle Scholar
  28. 28.
    Wykrzykowska J, Lehman S, Williams G, Parker JA, Palmer MR, Varkey S, et al. Imaging of inflamed and vulnerable plaque in coronary arteries with 18F-FDG PET/CT in patients with suppression of myocardial uptake using a low-carbohydrate, high-fat preparation. J Nucl Med. 2009;50:563–8.PubMedCrossRefGoogle Scholar
  29. 29.
    •• Williams G, Kolodny GM. Suppression of myocardial 18F-FDG uptake by preparing patients with a high-fat, low-carbohydrate diet. Am J Roentgenol. 2008;190:W151–6. One of the seminal papers about the technique to reduce myocardial 18F-FDG uptake.CrossRefGoogle Scholar
  30. 30.
    Harisankar CN, Mittal BR, Agrawal KL, Abrar ML, Bhattacharya A. Utility of high fat and low carbohydrate diet in suppressing myocardial FDG uptake. J Nucl Cardiol. 2011;18:926–36.PubMedCrossRefGoogle Scholar
  31. 31.
    Lum DP, Wandell S, Ko J, Coel MN. Reduction of myocardial 2-deoxy-2-[18F]fluoro-D-glucose uptake artifacts in positron emission tomography using dietary carbohydrate restriction. Mol Imaging Biol. 2002;4:232–7.PubMedCrossRefGoogle Scholar
  32. 32.
    Dilsizian V, Bacharach SL, Beanlands RS, Bergmann SR, Delbeke D, Gropler RJ, et al. PET Myocardial Perfusion and Metabolism Clinical Imaging. J Nucl Cardiol 2009;16. doi: 10.1007/s12350-009-9094-9. Available at: Accessed 24 Jan 2013.
  33. 33.
    Holly TA, Abbott BG, Al-Mallah M, Calnon DA, Cohen MC, DiFilippo, et al. Single photon-emission computed tomography. J Nucl Cardiol. 2010;17:941–73.PubMedCrossRefGoogle Scholar
  34. 34.
    Blankstein R, Naya M, Osborne M, Kim C, Murthy V, Kwong R, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoid. J Am Coll Cardiol. 2011;59:E1310.CrossRefGoogle Scholar
  35. 35.
    Dweck MR, Jones C, Joshi NV, Fletcher AM, Richardson H, White A, et al. Assessment of valvular calcification and inflammation by positron emission tomography in patients with aortic stenosis. Circulation. 2012;125:76–86.PubMedCrossRefGoogle Scholar
  36. 36.
    Pierre-Louis B, Prasad A, Frishman WH. Cardiac manifestations of sarcoidosis and therapeutic options. Cardiol Rev. 2009;17:153–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Soejima K, Yada H. The work-up and management of patients with apparent or subclinical cardiac sarcoidosis: with emphasis on the associated heart rhythm abnormalities. J Cardiovasc Electrophysiol. 2009;20:578–83.PubMedCrossRefGoogle Scholar
  38. 38.
    Chiu CZ, Nakatani S, Zhang G, Tachibana T, Ohmori F, Yamagishi M, et al. Prevention of left ventricular remodeling by long-term corticosteroid therapy in patients with cardiac sarcoidosis. Am J Cardiol. 2005;95:143–6.PubMedCrossRefGoogle Scholar
  39. 39.
    Yazaki Y, Isobe M, Hiroe M, Morimoto S, Hiramitsu S, Nakano T, et al. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol. 2001;88:1006–10.PubMedCrossRefGoogle Scholar
  40. 40.
    •• Mantini N, Williams Jr B, Stewart J, Rubinsztain L, Kacharava A. Cardiac sarcoid: a clinician's review on how to approach the patient with cardiac sarcoid. Clin Cardiol. 2012;35:410–5. Recent review paper summarizing several current concepts in the diagnosis and managements of patients with cardiac sarcoidosis.PubMedCrossRefGoogle Scholar
  41. 41.
    Ohira H, Tsujino I, Ishimaru S, Oyama N, Takei T, Tsukamoto E, et al. Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging. 2008;35:933–41.PubMedCrossRefGoogle Scholar
  42. 42.
    Bargout R, Kelly RF. Sarcoid heart disease: clinical course and treatment. Int J Cardiol. 2004;97:173–82.PubMedCrossRefGoogle Scholar
  43. 43.
    ••Matthews R, Bench T, Meng H, Franceschi D, Relan N, Brown DL. Diagnosis and monitoring of cardiac sarcoidosis with delayed-enhanced MRI and 18F-FDG PET-CT. J Nucl Cardiol. 2012;19:807–10. Interesting case-report illustrating the differential information provided by 18F-FDG PET and cardiac MRI.PubMedCrossRefGoogle Scholar
  44. 44.
    Yazaki Y, Isobe M, Hayasaka M, Tanaka M, Fujii T, Sekiguchi M. Cardiac sarcoidosis mimicking hypertrophic cardiomyopathy: clinical utility of radionuclide imaging for differential diagnosis. Jpn Circ J. 1998;62:465–8.PubMedCrossRefGoogle Scholar
  45. 45.
    Betensky BP, Tschabrunn CM, Zado ES, Goldberg LR, Marchlinski FE, Garcia FC, et al. Long-term follow-up of patients with cardiac sarcoidosis and implantable cardioverter-defibrillators. Hear Rhythm. 2012;9:884–91.CrossRefGoogle Scholar
  46. 46.
    Haraki T, Ueda K, Shintani H, Hayashi T, Taki J, Mabuchi H. Spontaneous development of left ventricular aneurysm in a patient with untreated cardiac sarcoidosis. Circ J. 2002;66:519–21.PubMedCrossRefGoogle Scholar
  47. 47.
    Deng JC, Baughman RP, Lynch III JP. Cardiac involvement in sarcoidosis. Semin Respir Crit Care Med. 2002;23:513–27.PubMedCrossRefGoogle Scholar
  48. 48.
    •• Ohira H, Tsujino I, Yoshinaga K. (1)F-Fluoro-2-deoxyglucose positron emission tomography in cardiac sarcoidosis. Eur J Nucl Med Mol Imaging. 2011;38:1773–83. This reference provides an excellent overview for imaging techniques and patient preparation.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Hicham Skali
    • 1
    • 2
  • Allison R. Schulman
    • 3
  • Sharmila Dorbala
    • 1
    • 2
    Email author
  1. 1.Department of Radiology, Division of Nuclear Medicine and Molecular imagingBostonUSA
  2. 2.Department of MedicineCardiovascular DivisionBostonUSA
  3. 3.Department of MedicineBrigham and Women’s Hospital, Harvard Medical SchoolBostonUSA

Personalised recommendations